Research funded by the UK’s Medical Research Council (MRC) has led to spin-out companies with an economic value of greater than £6.1 ($7.5) billion, according to a new report. The report looked at the 206 spin-outs for which there was Pitchbook data. These companies accounted for around… Read More
Sentinal4D, a spinout company from The Institute of Cancer Research (ICR), London, has been announced to the public after closing its first round of funding. The new company aims to accelerate drug discovery and development to target drugs to patients, using patented artificial intelligence-driven methods for personalised… Read More
Orakl Oncology has announced an €11 million seed funding round, led by Singular, with support from Bpifrance including the Grand Prix i-Lab, and participation from existing investors. The new funding will be used to accelerate the company’s growth and support the launch of two new commercial products,… Read More
This is the latest episode of the free DDW narrated podcast, titled ‘Exciting start-ups and developments in drug discovery’, which covers two articles written for DDW Volume 24 – Issue 1, Winter 2022/2023. They are called: ‘What Lithuania offers life sciences start-ups’ and ‘… Read More
Start-up Starget Pharma has raised $5.1 million in funding to support development of its radioligand-based therapies that target tumour cells with focused radiation. The investment was secured from Cancer Focus, a fund established in collaboration with the MD Anderson Cancer Center at the University of Texas. Read More
Dr Christine Allen, Co-Founder and CEO of Intrepid Labs tells Lu Rahman why the company’s technology has the ability to streamline the drug development process and improve the success rate of getting drugs to market. Intrepid Labs is the first spin-off from the University of Toronto’s Acceleration Consortium, which received… Read More
A group of former Pfizer employees have created their own businesses based at and supported by Discovery Park, a life sciences community in Kent, UK. The new businesses are all contract research organisations (CROs), namely Biowaived, Matheus Engineering and Particology. Their launch has been supported by… Read More
Six teams have been accepted onto Phase II of the Cancer Tech Accelerator, the entrepreneur training programme from Capital Enterprise dedicated to supporting cutting-edge oncology technology commercialisation. Selected from the 25 teams that took part in Phase I, three of the Phase II project teams will… Read More
DDW Editor Reece Armstrong speaks to Dr Steven Powell, co-founder of Glen Clova Scientific (GCS), about the company’s approach of using virus-like particles (VLPs) to treat conditions such as eczema and asthma, and what the current market looks like for this therapy area. Spun-out of the Univeristy of Dundee in… Read More
Closed Loop Medicine has joined the NVIDIA Inception accelerator programme, designed to nurture start-ups and early-stage companies revolutionising industries with technological advancements. The programme supports all stages of a start-up’s life cycle, providing access to the latest tools, expertise, and a network of venture capitalist investors,… Read More
UK biotech Myricx Bio has raised £90 ($114) million Series A financing to support the development of its N-Myristoyltransferase inhibitor (NMTi) antibody-drug conjugate (ADC) therapeutics. The round was co-led by new investors Novo Holdings and Abingworth, with additional support from British Patient Capital, Cancer Research Horizons… Read More
Genomic medicine developer Exsilio Therapeutics has emerged from stealth with $82 million in Series A financing. The funding was co-led by Novartis Venture Fund and Delos Capital, with participation from OrbiMed, Insight Partners, JP Morgan Life Sciences Private Capital, CRISPR Therapeutics, Innovation Endeavors, Invus, Arc Ventures,… Read More
A new accelerator programme at Alderley Park has been launched to support innovation and growth in the region. Bruntwood SciTech’s Life Science Accelerator programme has been designed to cater to the unique needs of early-stage life science companies from across the UK, offering comprehensive support and… Read More
This is the latest episode of the free DDW narrated podcast, titled “The future climate and landscape for drug discovery” which covers three written for Volume 24 – Issue 1, Winter 2022/2023 of DDW. They are called: Pharma’s important climate and What will the… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. The ongoing innovation and development in the drug discovery sector relies on a number… Read More
News round-up for 29 April – 3 May by DDW Multimedia Editor Megan Thomas. The ongoing innovation and development in the drug discovery sector relies on a number of moving parts, one of which is financial support and backing. Whether it is successful seed funding or dedicated investment,… Read More
